The combination therapy of Afantinid (a second‐generation EGFR inhibitor) and Pomalidomide (TNF inhibitor) has been‐shown to cause a decrease in GBM cell growth (Luo et al. 2020). This evidence concerns the gene TNF and glioblastoma.